Adjunct to diet & standard care therapy including moderate- to high-intensity statin therapy alone or in combination w/ other lipid-lowering therapy to reduce risk of MI, stroke & coronary revascularization in adults w/ atherosclerotic CV disease. Reduction of elevated LDL-C in adults w/ primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH): Adjunct to diet & statin therapy w/ or w/o other lipid-lowering therapies in patients requiring additional lowering of LDL-C, or alone or in combination w/ non-statin lipid-lowering therapies for patients whom statin is contraindicated. Adjunct to diet & other LDL-lowering therapies in adults & ped patients ≥10 yr w/ HoFH requiring additional lowering of LDL-C. Adjunct to diet & other LDL-C-lowering therapies eg, statins, ezetimibe in ped patients ≥10 yr w/ HeFH requiring additional lowering of LDL-C.
SC Adult w/ established CV disease or primary hyperlipidemia including HeFH & ped patient ≥10 yr w/ HeFH 140 mg every 2 wk or 420 mg once mthly. HoFH 420 mg once mthly.
Discontinue use if hypersensitivity reactions occur. Avoid inj into areas w/ scars or stretch marks; tender, bruised, red or indurated skin. Latex-sensitive individuals. Severe hepatic impairment. Pregnancy & lactation. Ped patients <10 yr. Elderly.
Sign Out
